Neogenomics INC Form 4 insider transactions

NeoGenomics CFO Jeffrey Scott Sherman disposed of 11,938 common shares to cover tax liabilities from restricted stock vesting.

NeoGenomics' President and Chief Operating Officer, Warren Stone, reported the surrender of 8,776 shares for tax obligations following restricted stock vesting.

Alicia C. Olivo, EVP, GC & Business Development at NeoGenomics, exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged 10b5-1 trading plan.

Alicia C. Olivo, EVP, GC & Business Development at NEOGENOMICS INC, sold 4,918 shares of common stock for $10 per share under a pre-arranged trading plan.

NeoGenomics EVP Alicia Olivo reported a disposition of 1,666 common shares to cover tax obligations from restricted stock vesting.

Neogenomics Inc.'s Chief Financial Officer, Jeffrey Scott Sherman, reported the acquisition of 20,000 shares of common stock in a transaction dated August 6, 2025.

NeoGenomics CEO Anthony P. Zook acquired 17,900 shares of common stock at $5.584 per share, increasing his direct holdings.

NeoGenomics Inc. EVP Alicia C. Olivo reported a routine disposition of 14 common shares to cover tax obligations related to restricted stock vesting.

Marjorie C. Green, a Director at NEOGENOMICS INC, has acquired 16,019 stock options and 22,964 restricted stock units, signaling increased insider equity alignment.

NEOGENOMICS Director Alison L. Hannah filed an amended Form 4 to correct a clerical error regarding the acquisition of 12,254 shares of common stock through the release of restricted stock units.

Felicia Williams, a Director at NEOGENOMICS INC, reported the vesting of 7,160 restricted stock units and the acquisition of new stock options and restricted stock units on June 1, 2025.

Neogenomics Inc. Director Stephen M. Kanovsky has reported the vesting of 12,254 restricted stock units into common stock and the acquisition of new stock options and restricted stock units as part of his compensation.

NEOGENOMICS Director Michael Aaron Kelly reported the vesting of 12,254 restricted stock units and the acquisition of new stock options and restricted stock units on June 1, 2025, increasing his direct and indirect beneficial ownership in the company.

Neogenomics Inc. Director Lynn A. Tetrault reported the vesting of restricted stock units into common stock and the grant of new stock options and restricted stock units, aligning her interests with shareholders.

NEOGENOMICS Director Alison L. Hannah has filed a Form 4, disclosing the vesting of 12,254 restricted stock units and the grant of new equity awards, including 16,107 stock options and 23,077 restricted stock units, effective June 1, 2025.

NEOGENOMICS Director Elizabeth Floegel has reported the vesting of restricted stock units and the grant of new stock options and restricted stock units, aligning her interests with shareholders.

NEOGENOMICS Inc. Director Neil Gunn has filed a Form 4 detailing the vesting of restricted stock units and the acquisition of new stock options and restricted stock units, increasing his beneficial ownership in the company.

NeoGenomics, Inc. CEO and Director Anthony P. Zook has reported the vesting of restricted stock units, related tax-driven share disposals, and substantial new equity grants, including stock options and restricted stock units.

NEOGENOMICS Director David Brian Perez reported the vesting of 12,254 restricted stock units into common stock and the acquisition of new stock options and restricted stock units on June 1, 2025, increasing his direct common stock holdings to 33,890 shares.

NeoGenomics Inc. Director Michael Aaron Kelly has increased his beneficial ownership in the company by purchasing 5,000 shares of common stock for $7.60 per share.

Chief Financial Officer Jeffrey Scott Sherman of Neogenomics Inc. reports acquisition and disposition of common stock and derivative securities.

Warren Stone, President & Chief Operating Officer of Neogenomics, reports the vesting of restricted stock units, tax-related share dispositions, and stock acquisitions, along with details of various stock option and performance stock unit grants.

Alicia C. Olivo, EVP, GC & Business Development at Neogenomics, reports the vesting of restricted stock units and associated tax withholding, along with holdings of stock options and performance stock units.

Director Lynn A. Tetrault reports acquisition of 7,000 shares of Neogenomics Inc. common stock at $8.1392 per share.

Director Stephen M. Kanovsky purchased 4,000 shares of Neogenomics Inc. common stock at $7.7811 per share on May 7, 2025, increasing his total holdings to 40,090 shares.

CEO Anthony P. Zook reports acquisition of Neogenomics shares and stock options in a Form 4 filing with the SEC.

Director David Brian Perez purchased 10,000 shares of Neogenomics Inc. at $7.63 per share on May 5, 2025.

Director Neil Gunn recently acquired shares of Neogenomics Inc. common stock at a price of $7.755 per share.

Jeffrey Scott Sherman, CFO of NeoGenomics, recently purchased 20,000 shares of the company's common stock at a price of $7.5052 per share.

Warren Stone, President & Chief Operating Officer of Neogenomics, reports the release of restricted stock units and associated tax withholding, along with details of stock options and restricted stock units granted.